International
Lung Cancer Summit7th October 2022
Lausanne University Hospital
Agora Pôle De Recherche Sur Le Cancer
Solange Peters, MD-PhD
Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at Lausanne University Hospital, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from Lausanne University Hospital, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.
Alfredo Addeo, MD
Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.
Following the great success of the virtual International Lung Cancer Summit (ILCS), we look forward to welcoming you to the 3rd edition of this interactive hybrid meeting. Similar to recent years, the ILCS will showcase latest discoveries and advances performed towards the treatment of lung cancer. The conference will leverage digital channels to provide with an exceptional outreach and opportunity for delegates from Medical Offices, Universities and Institutes to interact with world-class Medical Oncologists and Industry Professionals working in the field of lung cancer treatment and research.
The ILCS constitutes an ideal platform to share knowledge and seamless treatment procedures with our local and international speakers from the USA, Spain, Ireland, Israel, South Africa, Austria and Switzerland.
Join us and get your certificate of attendance during the conference. This meeting is accredited and CME-certified by the:
• Swiss Society of Medical Oncology: 5 credit points
• European Accreditation Council for Continuing Medical Education (EACCME): 4 credit points
Friday, 7 October 2022 – Live In Lausanne
Indicated Time Zone: Central European Summer Time (CEST)
10.00
Welcome by Chairs
Solange Peters & Alfredo Addeo
10.02
The power of pathology: biomarkers and targets we are testing today
Sabina Berezowska (Switzerland)
10.20
The many faces of EGFR mutations: each a different target
Alessandra Curioni (Switzerland)
10.45
ALK: old known with new expanded therapeutic options
Sze-Wai Chan (South Africa)
11.15
Open discussion & coffee break
11.30
Drugging the undruggables: the advent of KRAS and HER2 in NSCLC
Jair Bar (Israel)
11.50
METex14 and RET: important oncogenic factors for our treatment decision
Maximilian Hochmair (Austria)
12.30
Satellite Symposium
Industry Symposium MSD:
“Surgery and immunooncology – advancing the outcomes in the peri-operative setting of early-stage NSCLC”
Speakers to be determined
14.00
Immunotherapies in good companionship: where do combination therapies make sense in advanced NSCLC – and where not?
Jarushka Naidoo (Ireland)
14.30
DEBATE:
OS vs. DFS in early NSCLC
Disease free survival is an adequate endpoint for immuno- and targeted therapies in adjuvant NSCLC
Noemi Reguart (Spain)
14.45
DEBATE:
OS vs. DFS in early NSCLC
OS is the only meaningful endpoint – also for adjuvant therapies
Wolf-Dieter Janthur (Switzerland)
15.00
Open discussion & coffee break
15.20
The path of immunotherapies to early NSCLC: my choice in stage I -III
Sandip Patel (USA)
15.50
Small Cell Lung Cancer: what are our options for SCLC in 1st and 2nd line today?
Stephen V. Liu (USA)
16.20
Do we follow our own commitments that we take away from congresses?
Panel Discussion With All
Join us in Lausanne:
Centre hospitalier universitaire vaudois – CHUV
Fondation ISREC, Bâtiment AGORA
Rue du Bugnon 25A
1005 Lausanne, Switzerland
or online right here!
Add this to your calendar
Google Calendar (Online)
Outlook Calendar (Open Downloaded File)-
Outlook On Microsoft Office 365 (Online) -
Outlook On The Web (Online) 
Apple Offline Calendar / iCal
Lung Cancer Summit LIVE ONLINE
When: 10:00 AM - 5:00 PM (CEST)
The International Lung Cancer Summit 2022 is made possible with the kind support by our partners with no influence on the content:
for sponsoring opportunities, please contact us at sponsoring@lungcancersummit.org
Add this to your calendar
- Google Calendar (Online)
- Outlook Calendar (Open Downloaded File)
- Outlook On Microsoft Office 365 (Online)
- Outlook On The Web (Online)
- Apple Offline Calendar / iCal
Lung Cancer Summit LIVE ONLINE
When: 10:00 AM - 5:00 PM (CEST)
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
